Past Events
2025 9th Annual General Meeting
Event Details
The 2025 9th Annual General Meeting took place on Friday, March 28, 2025 at 9AM KST at the Daejeon Convention Center, 3FL conference Hall, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea
Presentation
Proposal Reference Material ( KR / EN )
Annual Report
Outcomes : KR / EN
Proposal No. 1 : Approval of the FY2024 Financial Statements | Approved
Proposal No. 2 : Approval of Director Remuneration Limit | Approved
Proposal No. 3 : Approval of Auditor Renumeration Limit | Approved
Proposal No. 4 : Approval of Amendments to the Articles of Incorporation | Approved
2024 Annual Result Conference Call
Event Details
Title: 2024 Annual Result Conference Call
Date and Time: Wednesday, 26 March 2025
UBS Asia Healthcare Corporate Day - Hong Kong 2024
Event Details
Title: UBS Asia Healthcare Corporate Day - Hong Kong 2024
Date and Time: Thursday, 28 - Friday, 29 November 2024
Orum Therapeutics to Hold Analyst Day in Korea
Event Details
Title: Orum Therapeutics to Hold Analyst Day in Korea
Date and Time: 10/18/24, All day
Orum Therapeutics to Host a Global Media Conference Call for the IPO
Event Details
Title: Orum to Host a Global Media Conference Call for the IPO
Date and Time: 10/7/24 10:00 KST, 10/6/24 20:00 EST
Orum Therapeutics Announces Three Presentations At AACR 2023
Poster Title:
PD-1-Cbl-bi TPS² preclinical poster
A novel antibody-enabled Dual-precision Targeted Protein Stabilization (TPS²) that augments anti-tumor immune response by targeting Cbl-b inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML
ORM-5029 predictive biomarker poster
Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader
Date and Time: 4/17/2023, 9:00 AM - 12:30 PM ET
Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151 at ASH 2022
Title: ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML.
Date and Time: 12/10/22 5:30 PM to 7:30 PM CST
Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML, At ASH 2022
Poster Title: ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
Date and Time: 12/10/2022, 5:30 PM to 7:30 PM CST
Orum Therapeutics Presents Preclinical Data At AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
Date and Time: 4/13/2022, 9:00 AM to 12:30 PM ET